Adult Vaccination – Updates, Developments and New Zoster Jab
Adult Vaccination – Updates, Developments and New Zoster Jab is a comprehensive Continuing Professional Development (CPD) course designed for healthcare professionals involved in adult immunisation, preventive healthcare, and elderly patient management. The course explores the latest advancements in adult vaccination programmes, emerging vaccine technologies, immunosenescence, and the expanding role of recombinant zoster vaccines such as Shingrix in reducing herpes zoster complications among older adults and immunocompromised populations. The course provides an overview of vaccine-preventable diseases that continue to pose significant health risks in ageing populations, including influenza, pneumococcal disease, respiratory syncytial virus (RSV), COVID-19, and herpes zoster. Learners will examine current immunisation recommendations, updates in national vaccination schedules, and evidence-based strategies to improve vaccine uptake in adults.
.jpg)
Learning Outcomes
What you'll learn
- Identify the vaccine-preventable diseases that currently pose the greatest risk in elderly populations.
- Define immunosenescence and outline its effects on immune function and vaccine response.
- Outline the clinical features, complications, and epidemiology of herpes zoster infection.
- Discuss new developments in vaccine production and immunisation strategies that benefit adults over the age of 65.
- Apply evidence from the Shingrix clinical trials to patient education and immunisation practice.
- Explain current recommendations for recombinant zoster vaccination in immunocompetent and immunocompromised adults.
- Evaluate barriers to adult vaccination uptake and strategies to improve vaccine acceptance.
- Promote evidence-based adult immunisation practices in primary care and community healthcare settings.
Learning Outcomes
What you'll learn
- Identify the vaccine-preventable diseases that currently pose the greatest risk in elderly populations.
- Define immunosenescence and outline its effects on immune function and vaccine response.
- Outline the clinical features, complications, and epidemiology of herpes zoster infection.
- Discuss new developments in vaccine production and immunisation strategies that benefit adults over the age of 65.
- Apply evidence from the Shingrix clinical trials to patient education and immunisation practice.
- Explain current recommendations for recombinant zoster vaccination in immunocompetent and immunocompromised adults.
- Evaluate barriers to adult vaccination uptake and strategies to improve vaccine acceptance.
- Promote evidence-based adult immunisation practices in primary care and community healthcare settings.
Modules
Module 1
Adult Vaccination and Ageing Populations
Module 2
Immunosenescence and Age-Related Immune Changes
Module 3
Herpes Zoster Infection and Clinical Features
Module 4
New Zoster Jab – Shingrix and Vaccine Developments
Module 5
Adult Immunisation Schedules and Clinical Practice
Module 6
Future Directions in Adult Vaccination
Module 7
Summary
Top reviews
No reviews yet.
You May Also Like
Come and Work
with Us!
Join us as a healthcare trainer providing practical sessions to professionals and workers.
Apply for Trainer RoleIn-Person Practical
Healthcare Training
Enroll in our accredited, hands-on practical training sessions to deliver better patientcentred care.
Apply for TrainingRefer &
Earn Rewards.
Invite healthcare professionals to join Care Learning and earn rewards for every successful referral.
Frequently Asked Questions
Immunosenescence refers to the gradual decline in immune system function associated with ageing, resulting in increased infection risk and reduced vaccine responsiveness.
Shingles occurs when latent varicella-zoster virus, which causes chickenpox, reactivates later in life due to reduced immune function.
Shingrix is a recombinant zoster vaccine used to prevent shingles and related complications such as postherpetic neuralgia.
Current recommendations generally include adults aged 50 years and older, as well as immunocompromised adults aged 19 years and older.
Common side effects include injection-site pain, fatigue, fever, headache, and muscle aches, which usually resolve within a few days.
Adult vaccines help prevent severe infections, reduce hospitalisations, improve quality of life, and protect vulnerable populations from preventable diseases.


.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)